|
|
Swedish Orphan Biovitrum AB est spécialisé dans le développement, la fabrication et la commercialisation de produits thérapeutiques destinés au traitement des maladies rares (hémophilie, maladies inflammatoires et auto-immunes, maladies métaboliques héréditaires, etc.). Le CA par source de revenus se répartit comme suit :
- ventes de produits (87,3%) ;
- royalties (9,6%) ;
- ventes de produits fabriqués en sous-traitance (3,1%).
La répartition géographique du CA (hors royalties) est la suivante : Europe (59,7%), Amérique du Nord (35,6%) et autres (4,7%).
Nombre d'employés : 1 559 personnes.
|
|
|
| 2020 | 2021 | Delta | | Hematology | 8 660.00 | 56.7% | 8 536.00 | 55% | -1.43% |
| Immunology | 5 415.00 | 35.5% | 5 780.00 | 37.2% | +6.74% |
| Specialty Care | 1 186.00 | 7.8% | 1 213.00 | 7.8% | +2.28% |
| SEK en Millions |
|
|
|
| 2020 | 2021 | Delta | | United States | 5 435.00 | 35.6% | 6 054.00 | 39% | +11.39% |
| Europe | 1 055.00 | 6.9% | 3 295.00 | 21.2% | +212.32% |
| France | 4 400.00 | 28.8% | 1 805.00 | 11.6% | -58.98% |
| Global | 1 301.00 | 8.5% | 1 251.00 | 8.1% | -3.84% |
| Germany | 1 445.00 | 9.5% | 1 233.00 | 7.9% | -14.67% |
| Rest of the World | 857.00 | 5.6% | 1 147.00 | 7.4% | +33.84% |
| Sweden | 720.00 | 4.7% | 678.00 | 4.4% | -5.83% |
| North America | 48.00 | 0.3% | 66.00 | 0.4% | +37.5% |
| SEK en Millions |
|
|
|
| Vote  | Nombre | Flottant | Autocontrôle | Flottant Total |
| Action A |
1 |
307 114 495 |
181 592 764 |
59.1% |
11 959 198 |
3.9% |
58.8% |
| Action B |
0.1 |
1 621 178 |
0 |
0.0% |
1 621 178 |
100.0% |
|
|
|
| Nom | Actions | % | | Investor AB (Investment Company) | 107 594 165 |
35,0% | | Fjärde AP-fonden | 20 532 666 |
6,69% | | Swedish Orphan Biovitrum AB (publ) | 8 918 672 |
2,90% | | Handelsbanken Fonder AB | 8 337 104 |
2,71% | | Swedbank Robur Fonder AB | 6 555 320 |
2,13% | | Schroder Investment Management Ltd. | 5 739 691 |
1,87% | | Norges Bank Investment Management | 5 222 809 |
1,70% | | The Vanguard Group, Inc. | 4 440 501 |
1,45% | | Lannebo Fonder AB | 4 014 452 |
1,31% | | AMF Fonder AB | 3 500 000 |
1,14% |
|
|
|
Swedish Orphan Biovitrum AB Tomtebodavägen 23A Solna, Stockholm 112 76 Phone : +46.8.697.20.00 Fax : +46.8.697.23.30 Web : http://www.sobi.com |
|
|
|
SWEDISH ORPHAN BIOVITRUM AB (PUBL)
Croissance soutenue, valorisation étonnamment abordable |
| | | |
 | CSL LIMITED | -3.62% | 93 394 |
 | SAMSUNG BIOLOGICS CO.,LTD. | -14.73% | 43 585 |
 | BIOGEN INC. | -17.01% | 29 160 |
 | WUXI BIOLOGICS (CAYMAN) INC. | -43.92% | 27 891 |
 | CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. | -22.41% | 23 276 |
 | UCB | -12.31% | 17 328 |
| SHANGHAI JUNSHI BIOSCIENCES CO., LTD. | 9.48% | 14 899 |
| BIOMARIN PHARMACEUTICAL INC. | -12.02% | 14 380 |
| WALVAX BIOTECHNOLOGY CO., LTD. | -11.07% | 12 137 |
 | GRIFOLS, S.A. | 16.77% | 11 974 |
| BLOOMAGE BIOTECHNOLOGY CORPORATION LIMITED | -19.48% | 8 992 |
| SK BIOSCIENCE CO.,LTD. | -44.44% | 7 338 |
| SHENZHEN KANGTAI BIOLOGICAL PRODUCTS CO., LTD. | -33.02% | 6 963 |
| CELLTRION HEALTHCARE CO., LTD. | -32.67% | 6 646 |
| HUALAN BIOLOGICAL ENGINEERING INC. | -42.79% | 4 553 |
| BEIJING TIANTAN BIOLOGICAL PRODUCTS CO., LTD. | -26.76% | 4 299 |
| APELLIS PHARMACEUTICALS, INC. | -16.56% | 4 202 |
| CANSINO BIOLOGICS INC. | -60.27% | 3 747 |
| GAN & LEE PHARMACEUTICALS. | -38.93% | 3 632 |
| INNOVENT BIOLOGICS, INC. | -61.37% | 3 482 |
Connexions : Swedish Orphan Biovitrum AB (publ) |
English (USA)
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Italiano
Nederlands (Nederland)
Nederlands (België)
bourse
Rapport
